Durin Technologies Inc., a Stratford-based innovator in neurodegenerative disease diagnostic test development, on Wednesday announced the appointment of Mert Sahin as CEO.
Sahin is a highly accomplished business executive with a track record of success in the life sciences sector. He brings to Durin more than 20 years of experience in life sciences, pharmaceuticals and medical devices, where he has demonstrated expertise in formulating and executing strategic go-to-market plans resulting in exceptional growth.
Sahin’s previous roles include executive positions at GE Healthcare, where he led marketing for its Imaging Business in the U.S. & Canada and was instrumental in growing the Molecular Imaging Business. He has held various commercial roles at Roche Diagnostics, Eurofins Genomics, Thermo Fisher Scientific and Dalan Animal Health.
Sahin also co-founded Boston BioProcess, which helps alternative protein ingredient companies transition from the lab to commercial scale. He holds a Ph.D. in cell biology from University of Hamburg, Germany.
In his new role, Sahin will lead Durin Technologies as it commercializes its novel diagnostic tests for Alzheimer’s and Parkinson’s diseases and develops its next generation of diagnostic tests for other diseases and disorders at their earliest stages.
Dr. Robert Nagele, Durin’s founder and chief scientific officer, said: “Dr. Sahin’s team-centric, lead-by-example leadership style and innovative approach to fostering growth make him an excellent fit for Durin’s aggressive growth plans. We’re confident that his strategic vision, expertise and determination will propel the company forward and allow Durin to seize the significant market opportunities available.”
“I am excited to join Durin, which will quickly become the innovation leader in neurodegenerative disease diagnostics,” Sahin said. “I look forward to working closely with the team to advance Durin to the next stage of its commercial success.”